Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Base Year Market Size (2025) | USD 995 Billion |
| Market Size (2026) | USD 1.06 Billion |
| Market Size (2031) | USD 1.44 Billion |
| Growth Rate (2026 - 2031) | 6.34% CAGR |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
South Korea Diabetes Drugs Market Analysis by Mordor Intelligence
South Korea diabetes drugs market size in 2026 is estimated at USD 1.06 billion, growing from 2025 value of USD 995 million with 2031 projections showing USD 1.44 billion, growing at 6.34% CAGR over 2026-2031. Accelerating growth stems from a rapid rise in disease prevalence, an ageing population, and continuing urban lifestyle shifts. Novel agents that combine glycaemic control with cardio-renal and weight-management benefits are reshaping prescribing behaviour. Digital health solutions that link medication, monitoring, and coaching are embedding themselves in routine care and opening new distribution channels. Meanwhile, supply security for glucagon-like peptide-1 (GLP-1) agents, stricter reimbursement discussions, and an evolving biosimilar pipeline shape the competitive climate
Key Report Takeaways
- By drug class, oral agents retained 46.95% revenue share in 2025, whereas non-insulin injectables are projected to rise at a 9.74% CAGR through 2031.
- By diabetes type, Type 2 cases accounted for 88.55% of the South Korea diabetes drugs market share in 2025 and are growing at a 7.42% CAGR to 2031.
- By drug origin, innovators held 64.05% of the South Korea diabetes drugs market size in 2025, yet biosimilars and generics are expanding at a 8.78% CAGR.
- By distribution channel, hospital pharmacies commanded 52.15% share in 2025, while online pharmacies show the fastest growth at 9.48% CAGR.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
South Korea Diabetes Drugs Market Trends and Insights
Drivers Impact Analysis*
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising diabetes prevalence and obesity burden | +1.8% | National; urban centres | Long term (≥ 4 years) |
| Preference for innovative and combination therapies | +1.2% | National; tertiary hospitals | Medium term (2-4 years) |
| Ageing population and urban lifestyles | +1.5% | Nationwide; Seoul-Incheon corridor | Long term (≥ 4 years) |
| Government reimbursement for novel agents | +0.9% | National | Medium term (2-4 years) |
| Digital health integration in diabetes management | +0.7% | Major cities | Short term (≤ 2 years) |
| Expanding R&D and global licensing collaborations | +0.6% | Nationwide with global partners | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Rising Diabetes Prevalence and Obesity Burden
Diabetes prevalence among adults aged 30 and older stood at 16.7% in 2024, making the disease Korea’s largest contributor to disability-adjusted life years. Obesity remains the key co-morbidity, as 73% of patients are overweight or obese.[1]Sung-Hee Oh, “Prevalence and Socioeconomic Burden of Diabetes Mellitus in South Korean Adults,” BMC Public Health, bmcpublichealth.biomedcentral.com Sugar intake trends deepen the challenge, with one-fifth of children exceeding recommended levels.[2]Hyejin Yu and Sang-Jin Chung, “Total Sugar Intake and Its Contributed Foods by Age Groups in Koreans,” Korean Journal of Community Nutrition, kjcn.or.kr Combined, these factors keep demand for established oral agents high while encouraging adoption of GLP-1 and sodium–glucose cotransporter-2 (SGLT-2)–based therapies. Lean diabetes, affecting 8.8% of patients, adds clinical complexity and underpins the need for personalised regimens.
Preference for Innovative and Combination Therapies
Updated Korean Diabetes Association guidance directs clinicians toward multi-mechanism regimens that optimise glycaemic control, cardiovascular protection, and renal outcomes. Phase 3 data on a triple agonist (efpeglenatide) targeting GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors highlight the climate of clinically oriented innovation. Low-dose lobeglitazone studies demonstrate non-inferior efficacy with fewer side effects, supporting wider adoption.[3]Soree Ryang et al., “REFIND Study on Low-Dose Lobeglitazone,” National Center for Biotechnology Information, ncbi.nlm.nih.govMarket appetite for fixed-dose combinations is reinforced by the approval of the triple oral agent metformin-dapagliflozin-sitagliptin in 2025, offering simpler dosing and better adherence.
Ageing Population and Urban Lifestyles
Adults aged 65 and older form Korea’s fastest-growing demographic segment, and this group shows the highest diabetes incidence. Urban residents face amplified exposure to sedentary jobs and processed food intake, further raising risk. The Act on Integrated Support for Community Care mandates home-centric, digitally enabled chronic disease care from 2026. Pharmaceutical companies thus focus on elder-friendly formulations, remote monitoring devices, and adherence aids.
Government Reimbursement for Novel Agents
National Health Insurance has introduced value-based frameworks that reward clinical benefit while containing costs. Generic price indices, however, remain higher than those in many peer countries. Manufacturers, therefore, invest in real-world evidence dossiers to strengthen cost-effectiveness arguments. Risk-sharing agreements and conditional listings create opportunities for high-value products that deliver measurable outcomes.
Restraints Impact Analysis*
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Stringent price cuts and reimbursement delays | -1.1% | National | Medium term (2-4 years) |
| Safety concerns, including ketoacidosis | -0.6% | Nationwide; elderly focus | Short term (≤ 2 years) |
| GLP-1 supply shortages and import caps | -0.8% | Nationwide; premium tier | Short term (≤ 2 years) |
| Clinical inertia despite guideline updates | -0.4% | Primary-care settings | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Stringent Price Cuts and Reimbursement Delays
Aggressive cost-containment under the Drug Expenditure Rationalization Plan compresses margins for novel therapies. Generic price indices declined only marginally from 4.79 to 3.40 versus the United States benchmark between 2020 and 2022, signifying limited relief. Manufacturers face protracted negotiations, prompting strategic launches of evidence packages that document cardio-renal benefits and long-term cost offsets.
Safety Concerns, Including Ketoacidosis
Expanded use of SGLT-2 inhibitors and GLP-1 agents triggers vigilance over rare but serious adverse events such as ketoacidosis in elderly or renal-impaired patients. Post-marketing surveillance studies are therefore front-loaded to secure clinician confidence, sometimes delaying promotional momentum.
*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.
Segment Analysis
By Drug Class: Oral Agents Lead Despite Injectable Innovation
The South Korea diabetes drugs market size for oral agents stood at USD 467.2 million in 2025, accounting for 46.95% of total sales. SGLT-2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors dominate prescribing volumes, supported by an 87.5% medication adherence rate among older adults. Nevertheless, non-insulin injectables are accelerating at a double-digit 9.74% CAGR as GLP-1 receptor agonists prove effective in weight control and cardio-renal protection. Cardiovascular-outcome trials continue to expand label indications, encouraging earlier initiation in high-risk patients. Low-dose lobeglitazone achieved non-inferior glucose reduction while lowering side-effect rates, exemplifying the quest for safer profiles. Fixed-dose triple combinations reduce pill burden and improve adherence, supporting treatment intensification without patient fatigue.
Within non-insulin injectables, patient acceptance is rising due to thinner needles, autoinjector devices, and once-weekly dosing. Biosimilar development and local fill-and-finish capacity are expected to moderate prices and alleviate shortages over the next five years. Oral GLP-1 development programmes, leveraging permeability enhancers and nanoparticle carriers, could blur class boundaries by 2030. Insulin remains indispensable for Type 1 and advanced Type 2 patients, and high-concentration formulations provide flexibility for dose-intensive regimens aimed at overcoming insulin resistance.
By Diabetes Type: Type 2 Dominance Drives Growth
In 2025, Type 2 patients generated 88.55% of the South Korea diabetes drugs market. Rising obesity and ageing lift the Type 2 case load, pushing forecasts toward 29.2% prevalence in men and 19.7% in women by 2030. Early combination therapy adoption aims to counter comorbidity clusters of hypertension and dyslipidaemia, improving overall outcomes. Type 1 population remains smaller yet technologically sophisticated, relying on sensor-integrated pumps and rapid-acting analogues for tight control. Paediatric Type 2 options are still limited to metformin, insulin, and liraglutide, indicating a clinical gap that innovators may address with youth-specific dosing and devices.
Lean diabetes, defined by lower body-mass index yet impaired insulin secretion, commands research attention for its unique pathophysiology. Herbal adjuncts, including red ginseng extract, demonstrated modest fasting glucose reductions in prediabetic adults, hinting at culturally familiar complementary options.
By Drug Origin: Biosimilars Gain Ground Against Innovators
Innovator brands commanded 64.05% of the South Korea diabetes drugs market share in 2025, but the biosimilar cohort is expanding at a 8.78% CAGR. Samsung Bioepis and GC Corp lead with diversified portfolios that encompass insulin, growth hormone, and monoclonal antibody biosimilars. Tiered pricing encourages early generic entry while rewarding innovation with temporary premium tiers. Domestic firms target complex injectables and high-volume oral agents, leveraging state incentives for biologics manufacturing. International alliances accelerate know-how transfer, as seen in HK inno.N’s GLP-1 collaboration.
Oramed’s oral insulin licence could erode innovators’ basal insulin share by offering needle-free convenience. Yet innovators retain differentiation through proprietary delivery systems, extended-release profiles, and continuous data connectivity.
By Distribution Channel: Digital Transformation Reshapes Access
Hospital pharmacies retained 52.15% of 2025 sales, reflecting the country’s specialist-led care model. The South Korea diabetes drugs market size handled by online pharmacies grew sharply after regulatory allowances for teleconsultations during the pandemic. Telemedicine platforms integrate e-prescriptions, point-of-care diagnostics, and doorstep delivery, giving chronic patients frictionless refills. Community pharmacies maintain patient education roles, particularly in suburban and rural locales where broadband constraints limit virtual care.
From 2026, community-care legislation will reimburse home-based monitoring devices and coaching apps. Continuous glucose monitors and sensor-augmented pumps require technical support, prompting certain chains to open specialist centres. Retail loyalty programmes that link drug refills with nutrition counselling and wearable data uploads differentiate offerings and build retention.
Geography Analysis
Regional diabetes patterns mirror demographic and lifestyle gradients. The Seoul-Incheon megalopolis exhibits the highest prevalence due to dense fast-food outlets, sedentary office work, and stress-related behaviours. Here, tertiary hospitals offer early access to GLP-1 and SGLT-2 therapies, accelerating urban uptake. Rural provinces, characterised by quicker population ageing and limited specialist supply, have less access to novel agents and rely more on generics and traditional oriental medicine. Government policy directs additional funding toward telemedicine and mobile clinics to equalise care standards.
Continuous-glucose-monitor penetration is highest in metropolitan school programmes aimed at early detection. Provincial centres adopt community-health-worker models that pair basic test strips with smartphone coaching, gradually bridging the technology gap. Manufacturing clusters in Gyeongbuk and Chungbuk provinces support local supply of metformin, gliclazide, and biosimilar insulin, reducing import dependence for essential medicines. National procurement frameworks adjust stock levels based on surge alerts for GLP-1 shortages broadcast by the World Health Organization. Urban lifestyle campaigns that promote active commuting and sugar-content labelling are likely to slow incidence growth in affluent districts, but socio-economic disparities persist, with lower-income boroughs reporting higher complication rates. Pharmacies in Busan are trialling blockchain-based traceability for high-value injectables, signalling regional experimentation with advanced supply-chain safeguards.
Regulatory Landscape
Drug approvals and post-marketing safety oversight for diabetes therapies sit with the Ministry of Food and Drug Safety (MFDS), while pricing and reimbursement are governed through the Ministry of Health and Welfare (MOHW) and the National Health Insurance Service (NHIS), with Health Insurance Review and Assessment Service (HIRA) playing a central role in coverage decisions. Reimbursement for antidiabetic medications continues to reference the long-standing General Principles for Antidiabetic Medications (2011 notification No. 2011-60), and the Korean Diabetes Association has been engaging stakeholders on revisions during 2026, highlighting the gap between modern, outcomes-driven guidance and legacy access criteria.
Alongside that, 2026 policy actions place emphasis on digital enablement and review efficiency. MFDS implemented a digital medical product framework effective January 2026 for healthcare support devices used in chronic disease management, supporting integration of connected monitoring and therapy-support tools alongside pharmacotherapy. Regulators have also expanded joint review initiatives with the European Medicines Agency and Japan’s Pharmaceuticals and Medical Devices Agency in 2026, pointing to continued efforts to streamline pathways for innovative products while retaining Korean requirements for safety surveillance and local market-access evidence.
Value Chain Analysis
The value chain covers discovery and clinical development (local and multinational), manufacturing and fill-finish, importation and distribution, and dispensing through hospital pharmacies, retail/community pharmacies, and fast-growing online channels linked to teleconsultation and e-prescriptions. In-country R&D remains a differentiator for local innovators, and Hanmi Pharmaceutical operates multiple research centers (Dongtan, Paltan, and Gwanggyo), using its long-acting technology and formulation capabilities to advance metabolic assets and create licensing optionality.
Manufacturing capacity and partnering are also being reinforced. The Special Act on Regulatory Support for Contract Development and Manufacturing Organizations for Biopharmaceuticals, promulgated in late 2025, targets strengthening South Korea’s biopharmaceutical CDMO base through 2026, with relevance for complex injectables and biologics supply resilience in areas such as GLP-1 and insulin. Cross-border licensing and supply agreements shape the chain as well, with Hanmi Pharmaceutical citing deals for metabolic portfolio assets with international partners such as Mexico’s Silanes, which supports how Korean-origin innovation can generate ex-Korea revenue while domestic commercialization remains sensitive to reimbursement terms and supply continuity.
Competitive Landscape
Competition is innovation-centred and moderately consolidated. Local champions such as Hanmi Pharmaceutical invest heavily in multi-agonist peptides, while multinationals protect franchise positions through lifecycle management that bundles drugs with digital services. Biosimilar entrants compress price points for mature insulins and DPP-4 inhibitors, pressuring innovators to pivot toward differentiated GLP-1 and dual-agonist pipelines. Strategic moves illustrate the dynamic such as Hanmi Pharmaceutical advanced efpeglenatide to Phase 3 for metabolic disease, HK inno.N licensed ecnoglutide, reinforcing the local GLP-1, GC Corp secured EU certification for a next-generation glucose monitor, expanding its value-chain footprint.
Digital partnerships between device manufacturers and pharmaceutical firms seek to embed prescription fills within remote-monitoring dashboards, thereby raising therapy stickiness and data-driven care optimisation. Real-world evidence repositories built on longitudinal insurance data help firms demonstrate economic value to payers, turning analytics into a critical competitive tool.
South Korea Diabetes Drugs Industry Leaders
Eli Lilly and Company
Novo Nordisk A/S
Sanofi
Merck & Co.
Hanmi Pharmaceutical
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Opportunity is concentrated where policy modernization and clinical innovation overlap, especially in obesity-linked Type 2 diabetes management that increasingly uses GLP-1-based regimens and fixed-dose combinations. Expansion of reimbursement criteria for GLP-1 receptor agonists is under active review during 2026 by MOHW and NHIS to better align access with current clinical practice. That supports room for manufacturers to strengthen real-world evidence and health-economic dossiers to broaden coverage and reduce access friction.
A second opportunity comes from accelerating locally developed pipelines and more flexible market-access contracting. Hanmi Pharmaceutical initiated a domestic Phase 3 clinical trial for efpeglenatide in Type 2 diabetes on April 13, 2026, reflecting active late-stage development within Korea that can shift competitive dynamics beyond imported brands. In 2026, the introduction of dual-pricing frameworks and more flexible contract systems enabling confidential net price negotiations with NHIS expands the toolkit for innovative therapies under tighter list-price controls. This encourages differentiation through long-acting and combination approaches that compete on outcomes and total-cost impact rather than unit price alone.
Recent Industry Developments
- June 2026: Hanmi Pharmaceutical dosed the first patient in a Korean Phase 3 clinical trial for efpeglenatide as an add-on treatment for type 2 diabetes. The development strengthens Hanmi's GLP-1/digenic strategy and supports local pipeline leadership in metabolic disease.
- June 2026: Hanmi Pharmaceutical initiated a Phase 2 clinical trial (NCT07527650) for HM15275 in subjects with type 2 diabetes. The initiative advances a locally developed multi-asset metabolic portfolio potentially attractive for partnerships or licensing.
- May 2026: Novo Nordisk A/S received MFDS approval for Kyinsu (insulin icodec/semaglutide), a once-weekly basal insulin and GLP-1 receptor agonist combination therapy for adults with type 2 diabetes. The approval solidifies local presence and expands access to integrated GLP-1/basal insulin regimen.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market covers the value of prescription diabetes medicines sold and used in South Korea, including insulin, oral anti-diabetics, non-insulin injectables, and combination drugs, across hospital, retail or community, and online channels.
Scope exclusions: Diabetes monitoring devices, test strips, and other non-drug care products are not counted in this market value.
Segmentation Overview
- By Drug Class
- Insulins
- Oral Anti-diabetic Drugs
- Non-Insulin Injectables
- Combination Drugs
- By Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- By Drug Origin
- Innovator Brands
- Biosimilars / Generics
- By Distribution Channel
- Hospital Pharmacies
- Retail / Community Pharmacies
- Online Pharmacies
Data Sources, Market Sizing, and Validation
Desk Research
Desk research was used to set the outer boundaries of the South Korea diabetes drug market and to build the starting pool of demand and pricing signals. For South Korea, this typically includes public health statistics and treatment guidance, which helps us understand how many people are treated, how therapy lines shift over time, and which drug classes show higher utilization.
We also review public sources such as Korea Disease Control and Prevention Agency releases, National Health Insurance Service and HIRA publications, Ministry of Food and Drug Safety notices, OECD Health Statistics, and peer-reviewed epidemiology and outcomes studies. In parallel, we use company filings, investor presentations, annual reports, and reputable news coverage to cross-check product launches, reimbursement changes, and any supply constraints that could affect sales in a given year. Where needed, we reference paid subscriptions for company financials and intelligence, news and financials, patent databases, and shipment-level import and export data to validate directionally. The items listed above are illustrative, and we also draw on other official documents and datasets to support collection, cross-checking, and clarification.
Primary Interviews and Surveys
Primary work focused on validating what desk research cannot fully show, especially class level uptake, switching patterns, and real-world pricing and access outcomes across hospital, community retail, and online channels. Interviews and surveys were conducted with clinicians, hospital pharmacists, payor and reimbursement experts, distributors, and local commercial teams, so assumptions on treated patients, adherence behavior, and mix by therapy class could be adjusted to better match actual practice.
Because this is a single-country market, we also checked whether treated mixes differ between major metro settings and non-metro care delivery, since that can influence the split between hospital dispensing and community pharmacy fulfillment.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 35% | CXOs: 15% | |
| Mid tier: 47% | Functional/Unit leaders: 26% | |
| Smaller Players: 18% | Managers: 59% |
Market-Sizing & Forecasting
Sizing starts from a top-down build where the treated diabetes pool in South Korea is constructed, then split by therapy type and channel, and finally converted to value using price and utilization assumptions. For this market, the demand pool assessment is shaped using diagnosed prevalence and treatment rates, therapy intensity by diabetes type, and the share of each drug class used within standard care pathways.
Key inputs that are tracked and refreshed include the Type 1 and Type 2 mix, shares of oral drugs versus injectables, GLP-1 and other non-insulin injectable adoption in eligible cohorts, insulin intensity in advanced patients, and the practical role of fixed-dose combinations. Pricing is handled through a blend of observed list and reimbursed price signals, expected class level price progression, and shifts toward biosimilars or generics where applicable. Totals are then corroborated through selective bottom-up checks such as sampled product-level price times volume logic, channel checks with pharmacies and distributors, and supplier revenue sanity checks where public disclosures allow it. Where gaps remain, we use class proxies and conservative range assumptions.
For forecasting, scenario analysis is used so growth can be tied back to specific drivers, then stress-tested for policy or supply events that could shift access. The forward view is anchored to expected prevalence and aging trends, anticipated reimbursement or access changes, and class level adoption curves that were validated through expert feedback, then translated into yearly value growth by channel.
Data Validation & Update Cycle
Validation is done in layers so the final numbers do not rely on a single input. We compare model outputs against independent signals such as public payer updates, utilization directionality discussed by experts, and major policy announcements. We then revisit any sharp year-to-year changes to confirm the driver is real and not a modeling artifact.
Variance checks are run at class and channel levels, followed by internal analyst reviews that look for inconsistent assumptions, sudden mix shifts, or pricing steps that do not match observed market behavior. If gaps remain, respondents are re-contacted to confirm the direction and the size of the effect before sign-off. Reports are refreshed annually, with interim updates when material events occur, and a final pre-delivery pass is completed so clients receive the most current view.
Mordor Intelligence's South Korea Diabetes Drugs Market Size Compared With Other Published Estimates
Published market values for diabetes drugs in South Korea often differ, even when the same end market is discussed. The spread usually comes from how the drug boundary is drawn, which year is treated as the base case, and how pricing and class mix are carried forward into the forecast window.
The table shows a clear range. In Mordor Intelligence's model, the value is limited to prescription diabetes medicines (insulins, oral anti-diabetics, non-insulin injectables, and combination drugs), and it is not expanded to include devices or broader diabetes care spending. Differences can also come from whether estimates assume faster GLP-1 uptake, how quickly biosimilar or generic penetration is applied, and whether currency timing and reimbursement updates are refreshed close to publication.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 0.99 B (2025) | |
| Industry Association A | USD 1.12 B (2025) | Often reported as a wider diabetes care spend number, where some adjacent costs and non-drug items can be blended in, and class boundaries are not always stated clearly. |
| Trade Journal B | USD 0.90 B (2025) | Can reflect a narrower view that emphasizes reimbursed volumes in select channels, which may undercount online fulfillment and some newer therapy uptake in the base year. |
Looking across the three figures, the main reasons for the gap are practical and traceable, which items are included, how class mix is treated, and how pricing and access updates are timed. By keeping the model tied to treated patients, therapy class usage, and channel level checks, the estimate can be reproduced and updated without relying on hidden inputs.
Key Questions Answered in the Report
What is the current value of the South Korea diabetes drugs market?
The market stands at USD 1.06 billion in 2026 and is forecast to reach USD 1.44 billion by 2031.
Which therapeutic class leads sales in the South Korea diabetes drugs market?
Oral antidiabetic agents lead with 46.95% of 2025 revenue, though non-insulin injectables are growing fastest.
How dominant is Type 2 diabetes in South Korea?
Type 2 cases contribute 88.55% of total drug revenue and are projected to expand further at a 7.42% CAGR through 2031.
What role do biosimilars play in market dynamics?
Biosimilars and generics are growing at 8.78% CAGR through 2031, steadily eroding innovators’ share and lowering therapy costs.
How is digital health transforming distribution?
Online pharmacies and telemedicine platforms are expanding at 9.48% CAGR through 2031, offering integrated prescription, delivery, and monitoring services.
What are the main challenges facing manufacturers?
Stringent price negotiations, GLP-1 supply constraints, and the need for real-world evidence to secure reimbursement are key hurdles.
Page last updated on:
